A Phase 3 interventional study of Ranolazine and Placebo in Coronary Artery Disease and Angina Pectoris, sponsored by Gilead Sciences. Completed at 218 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-15.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ranolazine in Coronary Artery Disease — none open to participants now, none under way, none of them phase 3. Ranolazine · Coronary Artery Disease.
Among the 15 studies testing ranolazine in Coronary Artery Disease, this one has the largest enrollment, is one of 4 that started in 2011, is one of 4 in phase 3, and was the 7th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →None of the 15 studies testing ranolazine in Coronary Artery Disease is open now. The open studies under Coronary Artery Disease, anywhere →
Ranolazine: first FDA approval 2006 (RANEXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 8
First in 2004; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,651 is above the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 50 across the 15 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 9 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
10 studies in Coronary Artery Disease by Gilead Sciences: none open now, none under way, none of them phase 3. Of 8 finished, 3 (38%) have results posted.
Among the 10 studies in Coronary Artery Disease by Gilead Sciences, this one has the largest enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 9th registered.
Gilead Sciences’s Coronary Artery Disease studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing ranolazine in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 10 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PCI for any indication (ACS or non-ACS). For the purposes of stratification at randomization, ACS will be defined as hospitalization for anginal pain or discomfort within the previous 24 hours to their hospitalization with any one (or more) of the following criteria:
i. Elevated troponin or creatinine kinase-MB (CK-MB) consistent with myocardial infarction (MI), as reported by local laboratory and measured prior to index PCI ii. Electrocardiographic changes (including transient changes) comprising new or presumably new ST segment depression ≥ 0.1 mV (≥ 1 mm), or ST segment elevation ≥ 0.1 mV (≥ 1 mm) in at least 2 contiguous leads, or new or presumably new Left Bundle Branch Block
Clinically stable post-PCI. Participants randomized in-hospital on day of planned discharge or in clinic are considered stable. Participants randomized in-hospital prior to day of planned discharge must meet all of the following criteria:
i. CK-MB \< 3 times the (ULN) at least 3 hours post-PCI, or if ≥ 3 times the ULN with evidence of decreasing CK-MB (decreased by at least 20% from the prior measurement) as reported by local laboratory. If CK-MB is not available, a participant must have evidence of normal or decreasing troponin levels (by at least 20% from the prior measurement) at least 3 hours post-PCI, as reported by local laboratory.
ii. Systolic blood pressure ≥ 90 mm Hg and not receiving pressors or inotropes iii. No current requirement for an intra-aortic balloon pump (IABP) or any left ventricular assist device iv. No current requirement for intravenous (IV) nitroglycerin
Exclusion Criteria:
Major complication during or after the index PCI (in the case of staged PCI, the last in the series) including:
i. Major bleeding (TIMI Bleeding classification or any bleeding requiring blood transfusion of ≥ 2 units of red blood cells) ii. Coronary perforation requiring treatment iii. Procedural complication requiring surgery (including CABG or peripheral vascular surgery)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ranolazine
Drug: Placebo
Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Also known as: Ranexa
Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study. Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization
Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days.
Time frame: Baseline through end of study (average 90 weeks)
Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death
Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.
Time frame: Baseline through end of study (average 90 weeks)
Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death
Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.
Time frame: Baseline through end of study (average 90 weeks)
Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction
Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.
Time frame: Baseline through end of study (average 90 weeks)
Participants were enrolled at study sites in the United States, Canada, Europe, Russia, and Israel. The first participant was screened on 03 November 2011. The last study visit occurred on 09 February 2015.
| Milestone | Ranolazine | Placebo |
|---|---|---|
| Started | 1332 | 1319 |
| Completed | 1029 | 1040 |
| Not completed | 303 | 279 |
| Withdrew: Death | 35 | 29 |
| Withdrew: Investigator-initiated early closure | 44 | 43 |
| Withdrew: Participant withdrew consent | 137 | 102 |
| Withdrew: Lost to follow-up | 37 | 51 |
| Withdrew: Adverse event | 26 | 15 |
| Withdrew: Protocol deviation | 9 | 20 |
| Withdrew: Investigator's discretion | 13 | 16 |
| Withdrew: Study terminated by sponsor | 2 | 3 |
Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days.
| percentage of participants | Ranolazine | Placebo |
|---|---|---|
| KM Estimate: 1 Month | 3.4 | 2.3 |
| KM Estimate: 6 Months | 11.3 | 10.0 |
| KM Estimate: 12 Months | 19.1 | 17.3 |
| KM Estimate: 1 Calendar Year | 20.2 | 18.9 |
| KM Estimate: 18 Months | 23.8 | 25.3 |
| KM Estimate: 24 Months | 27.6 | 29.4 |
| KM Estimate: 2 Calendar Years | 30.7 | 31.0 |
| KM Estimate: 30 months | 31.1 | 33.8 |
| KM Estimate: 36 Months | 32.2 | 37.8 |
| KM Estimate: 3 Calendar Years | NA | 37.8 |
Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.
| percentage of participants | Ranolazine | Placebo |
|---|---|---|
| KM Estimate: 1 Month | 0.2 | 0.1 |
| KM Estimate: 6 Months | 0.5 | 0.2 |
| KM Estimate: 12 Months | 0.5 | 0.5 |
| KM Estimate: 1 Calendar Year | 0.5 | 0.5 |
| KM Estimate: 18 Months | 0.5 | 0.8 |
| KM Estimate: 24 Months | 0.5 | 0.9 |
| KM Estimate: 2 Calendar Years | 0.7 | 0.9 |
| KM Estimate: 30 months | 0.7 | 0.9 |
| KM Estimate: 36 Months | 0.7 | 0.9 |
| KM Estimate: 3 Calendar Years | 0.7 | 0.9 |
Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.
| percentage of participants | Ranolazine | Placebo |
|---|---|---|
| KM Estimate: 1 Month | 0.2 | 0.1 |
| KM Estimate: 6 Months | 0.6 | 0.4 |
| KM Estimate: 12 Months | 1.0 | 0.9 |
| KM Estimate: 1 Calendar Year | 1.1 | 1.0 |
| KM Estimate: 18 Months | 1.5 | 1.4 |
| KM Estimate: 24 Months | 1.7 | 1.7 |
| KM Estimate: 2 Calendar Years | 1.9 | 1.7 |
| KM Estimate: 30 months | 1.9 | 1.7 |
| KM Estimate: 36 Months | 1.9 | 1.7 |
| KM Estimate: 3 Calendar Years | 1.9 | 1.7 |
Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days.
| percentage of participants | Ranolazine | Placebo |
|---|---|---|
| KM Estimate: 1 Month | 1.2 | 0.6 |
| KM Estimate: 6 Months | 3.8 | 3.3 |
| KM Estimate: 12 Months | 5.8 | 5.7 |
| KM Estimate: 1 Calendar Year | 6.2 | 6.2 |
| KM Estimate: 18 Months | 7.3 | 8.5 |
| KM Estimate: 24 Months | 8.7 | 9.4 |
| KM Estimate: 2 Calendar Years | 10.0 | 9.4 |
| KM Estimate: 30 months | 10.9 | 10.1 |
| KM Estimate: 36 Months | 10.9 | 13.4 |
| KM Estimate: 3 Calendar Years | 10.9 | 13.4 |
Collected over Baseline through end of study drug treatment (average exposure 72 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranolazine | — | 516/1,322 (39%) | 665/1,322 (50.3%) |
| Placebo | — | 485/1,297 (37.4%) | 531/1,297 (40.9%) |
| Event | Ranolazine | Placebo |
|---|---|---|
| Angina pectorisCardiac disorders | 125/1322 | 114/1297 |
| Angina unstableCardiac disorders | 58/1322 | 71/1297 |
| Chest painGeneral disorders | 37/1322 | 24/1297 |
| Acute myocardial infarctionCardiac disorders | 28/1322 | 29/1297 |
| SyncopeNervous system disorders | 25/1322 | 13/1297 |
| Cardiac failure congestiveCardiac disorders | 20/1322 | 6/1297 |
| Non-cardiac chest painGeneral disorders | 19/1322 | 19/1297 |
| Myocardial infarctionCardiac disorders | 18/1322 | 18/1297 |
| Atrial fibrillationCardiac disorders | 12/1322 | 14/1297 |
| Coronary artery diseaseCardiac disorders | 14/1322 | 11/1297 |
| Event | Ranolazine | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 240/1322 | 119/1297 |
| ConstipationGastrointestinal disorders | 167/1322 | 71/1297 |
| Angina pectorisCardiac disorders | 161/1322 | 156/1297 |
| NauseaGastrointestinal disorders | 123/1322 | 63/1297 |
| FatigueGeneral disorders | 99/1322 | 74/1297 |
| HeadacheNervous system disorders | 98/1322 | 89/1297 |
| Chest painGeneral disorders | 97/1322 | 92/1297 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 89/1322 | 89/1297 |
| CoughRespiratory, thoracic and mediastinal disorders | 69/1322 | 51/1297 |
Safety Analysis Set: participant who were randomized and received at least one dose of study drug
| Age, Continuous(years) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Mean | 63.4 ± 10.51 | 63.4 ± 10.06 | 63.4 ± 10.29 |
| Age, Customized(participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| < 65 Years | 714 | 719 | 1433 |
| 65-74 Years | 402 | 383 | 785 |
| ≥ 75 Years | 206 | 195 | 401 |
| Sex: Female, Male(Participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Female | 276 | 260 | 536 |
| Male | 1046 | 1037 | 2083 |
| Race/Ethnicity, Customized(participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 16 | 10 | 26 |
| Black or African American | 49 | 43 | 92 |
| Native Hawaiian or Pacific Islander | 2 | 1 | 3 |
| White | 1203 | 1196 | 2399 |
| Other | 29 | 28 | 57 |
| Not Permitted | 23 | 16 | 39 |
| Race/Ethnicity, Customized(participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 72 | 64 | 136 |
| Not Hispanic or Latino | 1219 | 1208 | 2427 |
| Not Reported | 28 | 24 | 52 |
| Unknown | 3 | 1 | 4 |
| Region of Enrollment(participants) | Ranolazine | Placebo | Total |
|---|---|---|---|
| Russian Federation | 154 | 168 | 322 |
| United States | 499 | 466 | 965 |
| United Kingdom | 16 | 17 | 33 |
| Spain | 80 | 87 | 167 |
| Canada | 80 | 85 | 165 |
| Austria | 12 | 15 | 27 |
| Czech Republic | 31 | 44 | 75 |
| Netherlands | 13 | 13 | 26 |
| Sweden | 19 | 25 | 44 |
| Belgium | 20 | 21 | 41 |
| Poland | 203 | 172 | 375 |
| Italy | 28 | 33 | 61 |
| Israel | 111 | 109 | 220 |
| France | 22 | 15 | 37 |
| Germany | 34 | 27 | 61 |
Showing the first 100 of 218 sites across 15 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine